HuGE Literature Finder
Records
1
-
30
| NAT2 and CYP2E1 polymorphisms and antituberculosis drug-induced hepatotoxicity in Peruvian patients. Molecular genetics & genomic medicine 2022 Jun e1987. Jaramillo-Valverde Luis, Levano Kelly S, Tarazona David D, Capristano Silvia, Zegarra-Chapoñan Roberto, Sanchez Cesar, Yufra-Picardo Velia M, Tarazona-Santos Eduardo, Ugarte-Gil Cesar, Guio Heinn |
| Homozygotes NAT2*5B slow acetylators are highly associated with hepatotoxicity induced by anti-tuberculosis drugs. Memorias do Instituto Oswaldo Cruz 2022 117 e210328. El-Jaick Kenia Balbi, Ribeiro-Alves Marcelo, Soares Marcos Vinícius Guimarães, Araujo Gabriela Eduardo França de, Pereira Gabriel Rodrigues Coutinho, Rolla Valeria Cavalcanti, Mesquita Joelma Freire De, De Castro Lia |
| A Rapid Pharmacogenomic Assay to Detect NAT2 Polymorphisms and Guide Isoniazid Dosing for Tuberculosis Treatment. American journal of respiratory and critical care medicine 2021 Aug . Verma Renu, Patil Sunita, Zhang Nan, Moreira Flora M F, Vitorio Marize T, Santos Andrea da S, Wallace Ellen, Gnanashanmugam Devasena, Persing David, Savic Rada, Croda Julio, Andrews Jason |
| Pharmacogenetics of interaction between depot medroxyprogesterone acetate and efavirenz, rifampicin, and isoniazid during treatment of HIV and tuberculosis. Pharmacogenetics and genomics 2021 Aug . Haas David W, Mngqibisa Rosie, Francis Jose, McIlleron Helen, Robinson Jennifer A, Kendall Michelle A, Baker Paxton, Mawlana Sajeeda, Badal-Faesen Sharlaa, Angira Francis, Omoz-Oarhe Ayotunde, Samaneka Wadzanai P, Denti Paolo, Cohn Susan E, |
| NAT2 Gene rs1041983 is Associated with Anti-Tuberculosis Drug Induced Hepatotoxicity Among Pediatric Tuberculosis in Bandung, Indonesia. The application of clinical genetics 2021 14 297-303. Headriawan Achmad, Pramono Alvinsyah Adhityo, Sukadi Abdurachman, Chairulfatah Alex, Maskoen Ani Melani, Nataprawira Heda Melin |
| A Systematic Review and Meta-analysis of Isoniazid Pharmacokinetics in Healthy Volunteers and Patients with Tuberculosis. Clinical therapeutics 2020 Oct . Hong Boi-Lam, D'Cunha Ronilda, Li Peizhi, Al-Shaer Mohammad H, Alghamdi Wael A, An Guohua, Peloquin Charl |
| The role of NAT2 polymorphism and methylation in anti-tuberculosis drug-induced liver injury in Mongolian tuberculosis patients. Journal of clinical pharmacy and therapeutics 2020 Jun 45 (3): 561-569. Zhang Dong, Hao Jinqi, Hou Ruili, Yu Yanqin, Hu Baocui, Wei Liq |
| Association of Drug Metabolic Enzyme Genetic Polymorphisms and Adverse Drug Reactions in Patients Receiving Rifapentine and Isoniazid Therapy for Latent Tuberculosis. International journal of environmental research and public health 2019 Dec 17 (1): . Yu Ya-Yen, Tsao Shih-Ming, Yang Wen-Ta, Huang Wei-Chang, Lin Ching-Hsiung, Chen Wei-Wen, Yang Shun-Fa, Chiou Hui-Ling, Huang Yi-W |
| Hepatotoxicity during TB treatment in people with HIV/AIDS related to NAT2 polymorphisms in Pernambuco, Northeast Brazil. Annals of hepatology 2019 Oct . Araujo-Mariz Carolline, Militão de Albuquerque Maria de Fátima P, Lopes Edmundo P, Ximenes Ricardo A A, Lacerda Heloísa R, Miranda-Filho Demócrito B, Lustosa-Martins Brena B, Pastor André Filipe P, Acioli-Santos Bartolom |
| Association of genetic polymorphisms of CYP2E1, NAT2, GST and SLCO1B1 with the risk of anti-tuberculosis drug-induced liver injury: a systematic review and meta-analysis. BMJ open 2019 Aug 9 (8): e027940. Yang Seungwon, Hwang Se Jung, Park Jung Yun, Chung Eun Kyoung, Lee Jangik |
Genomewide Association Study Confirming the Association of NAT2 with Susceptibility to Antituberculosis Drug-Induced Liver Injury in Thai Patients.
Antimicrobial agents and chemotherapy 2019 Aug 63 (8): . Suvichapanich Supharat, Wattanapokayakit Sukanya, Mushiroda Taisei, Yanai Hideki, Chuchottawon Charoen, Kantima Tassawan, Nedsuwan Supalert, Suwankesawong Wimon, Sonsupap Cholticha, Pannarunothai Roongkarn, Tumpattanakul Sukanya, Bamrungram Warawut, Chaiwong Achara, Mahasirimongkol Surakameth, Mameechai Sasithorn, Panthong Weerapat, Klungtes Nantawan, Munsoo Amara, Chauychana Udomrat, Maneerat Molrudee, Fukunaga Koya, Omae Yosuke, Tokunaga Katsus |
| Relevance of NAT2 genotype to anti-tuberculosis drug-induced hepatotoxicity in a Chinese Han population. The journal of gene medicine 2019 May e3096. Lu Lihuan, Tao Bilin, Wei Haixu, Chen Hongbo, He Xiaomin, Pan Hongqiu, Yang Miaomiao, Yi Honggang, Tang Shaow |
| Association of Nat2 Gene Polymorphism with Antitubercular Drug-induced Hepatotoxicity in the Eastern Uttar Pradesh Population. Cureus 2019 Apr 11 (4): e4425. Yadav Divya, Kumar Rahul, Dixit Rakesh K, Kant Surya, Verma Ajay, Srivastava Kanchan, Singh S K, Singh Sarve |
| Effects of genetic variability on rifampicin and isoniazid pharmacokinetics in South African patients with recurrent tuberculosis. Pharmacogenomics 2019 Feb . Naidoo Anushka, Chirehwa Maxwell, Ramsuran Veron, McIlleron Helen, Naidoo Kogieleum, Yende-Zuma Nonhlanhla, Singh Ravesh, Ncgapu Sinaye, Adamson John, Govender Katya, Denti Paolo, Padayatchi Nes |
| The Influence of Pharmacogenetic Variants in HIV/Tuberculosis Coinfected Patients in Uganda in the SOUTH Study. Clinical pharmacology and therapeutics 2019 Feb . Calcagno Andrea, Cusato Jessica, Sekaggya-Wiltshire Christine, von Braun Amrei, Motta Ilaria, Turyasingura Grace, Castelnuovo Barbara, Fehr Jan, Di Perri Giovanni, Lamorde Mohamm |
| NAT2 ultra-slow acetylator and risk of anti-tuberculosis drug-induced liver injury: a genotype-based meta-analysis. Pharmacogenetics and genomics 2018 Jul 28 (7): 167-176. Suvichapanich Supharat, Fukunaga Koya, Zahroh Hilyatuz, Mushiroda Taisei, Mahasirimongkol Surakameth, Toyo-Oka Licht, Chaikledkaew Usa, Jittikoon Jiraphun, Yuliwulandari Rika, Yanai Hideki, Wattanapokayakit Sukanya, Tokunaga Katsus |
| The association between the NAT2 genetic polymorphisms and risk of DILI during anti-TB treatment: a systematic review and meta-analysis. British journal of clinical pharmacology 2018 Jul . Zhang Min, Wang Shuqiang, Wilffert Bob, Tong Rongsheng, van Soolingen Dick, van den Hof Susan, Alffenaar Jan-Will |
| Effect of Genetic Variation of NAT2 on Isoniazid and SLCO1B1 and CES2 on Rifampin Pharmacokinetics in Ghanaian Children with Tuberculosis. Antimicrobial agents and chemotherapy 2017 Dec . Dompreh Albert, Tang Xiaoli, Zhou Jianlin, Yang Hongmei, Topletz Ariel, Adu Ahwireng Eugene, Antwi Sampson, Enimil Antony, Langaee Taimour, Peloquin Charles A, Court Michael H, Kwara Awewu |
| N-acetyltransferase gene polymorphisms & plasma isoniazid concentrations in patients with tuberculosis. The Indian journal of medical research 2017 Jan 145 (1): 118-123. Hemanth Kumar A K, Ramesh K, Kannan T, Sudha V, Haribabu Hemalatha, Lavanya J, Swaminathan Soumya, Ramachandran Geet |
| Association and clinical utility of NAT2 in the prediction of isoniazid-induced liver injury in Singaporean patients. PloS one 2017 12 (10): e0186200. Chan Sze Ling, Chua Angeline Poh Gek, Aminkeng Folefac, Chee Cynthia Bin Eng, Jin Shengnan, Loh Marie, Gan Suay Hong, Wang Yee Tang, Brunham Liam |
| Factors associated with anti-TB drug-induced hepatotoxicity and genetic polymorphisms in indigenous and non-indigenous populations in Brazil. Tuberculosis (Edinburgh, Scotland) 2016 Dec 101 15-24. Heinrich Melissa M, Zembrzuski Verônica M, Ota Marcos M, Sacchi Flavia P, Teixeira Raquel L F, Cabello Acero Pedro H, Cunha Geraldo Marcelo, Souza-Santos Reinaldo, Croda Julio, Basta Paulo |
| Genetic polymorphisms of N-acetyltransferase 2 & susceptibility to antituberculosis drug-induced hepatotoxicity. The Indian journal of medical research 2016 Dec 144 (6): 924-928. Sharma Surendra K, Jha Brajesh Kumar, Sharma Abhishek, Sreenivas V, Upadhyay Vishwanath, Jaisinghani Chandrita, Singla Rohit, Mishra Hemant Kumar, Soneja Mani |
| NAT2 slow acetylator associated with anti-tuberculosis drug-induced liver injury in Thai patients. The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease 2016 Oct 20 (10): 1364-1369. Wattanapokayakit S, Mushiroda T, Yanai H, Wichukchinda N, Chuchottawon C, Nedsuwan S, Rojanawiwat A, Denjanta S, Kantima T, Wongyai J, Suwankesawong W, Rungapiromnan W, Kidkeukarun R, Bamrungram W, Chaiwong A, Suvichapanich S, Mahasirimongkol S, Tokunaga |
| NAT2 Genotypes in Moroccan Patients with Hepatotoxicity Due to Antituberculosis Drugs. Genetic testing and molecular biomarkers 2016 Aug . Guaoua Soukaina, Ratbi Ilham, El Bouazzi Omaima, Hammi Sanaa, Tebaa Amina, Bourkadi Jamal Eddine, Soulaymani Bencheikh Rachida, Sefiani Abdelaz |
| Genotype and allele frequencies of isoniazid-metabolizing enzymes NAT2 and GSTM1 in Latvian tuberculosis patients. Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy 2016 Jul 22 (7): 472-7. Igumnova Viktorija, Capligina Valentina, Krams Alvils, Cirule Andra, Elferts Didzis, Pole Ilva, Jansone Inta, Bandere Dace, Ranka Rena |
| NAT2 variants are associated with drug-induced liver injury caused by anti-tuberculosis drugs in Indonesian patients with tuberculosis. Journal of human genetics 2016 Jun 61 (6): 533-7. Yuliwulandari Rika, Susilowati Retno Wilujeng, Wicaksono Britanto Dani, Viyati Kencono, Prayuni Kinasih, Razari Intan, Kristin Erna, Syafrizal , Subagyo , Sri Diana Eva, Setiawati Suci, Ariyani Aziza, Mahasirimongkol Surakameth, Yanai Hideki, Mushiroda Taisei, Tokunaga Katsus |
| Risk factors of isoniazid-induced hepatotoxicity in Tunisian tuberculosis patients. The pharmacogenomics journal 2016 Apr . Ben Fredj N, Gam R, Kerkni E, Chaabane A, Chadly Z, Boughattas N, Aouam |
| tagSNP rs1495741 as a useful molecular marker to predict antituberculosis drug-induced hepatotoxicity. Pharmacogenetics and genomics 2016 Apr . Chamorro Julián G, Castagnino Jorge P, Musella Rosa M, Nogueras Mabel, Frías Ana, Visca Mabel, Aidar Omar, Costa Lucas, de Larrañaga Gabriela |
| Prevention of isoniazid toxicity by NAT2 genotyping in Senegalese tuberculosis patients. Toxicology reports 2016 3 826-831. Toure A, Cabral M, Niang A, Diop C, Garat A, Humbert L, Fall M, Diouf A, Broly F, Lhermitte M, Allorge |
| Polymorphisms of NAT2, CYP2E1, GST, and HLA related to drug-induced liver injury in indonesian tuberculosis patients. International journal of mycobacteriology 0 7 (4): 380-386. Perwitasari Dyah Aryani, Darmawan Endang, Mulyani Ully Adhi, Vlies Pieter Van Der, Alffenaar Jan-Willem C, Atthobar Jarir, Wilffert B |
- Page last reviewed:Jul 25, 2022
- Page last updated:Aug 16, 2022
- Content source: